Rivaroxaban Inhibits Platelet‐Driven NOX2‐Dependent Oxidative Injury to Endothelium

BACKGROUND: Endothelial dysfunction is a hallmark of cardiovascular disease, driven by oxidative stress, inflammation, and platelet activation. We hypothesized that the FXa inhibitor rivaroxaban, alone or combined with clopidogrel, could counteract platelet-induced oxidative injury to the endothelium and preserve endothelial function. METHODS: We conducted a prospective multicenter cohort clinical study in patients on chronic antiplatelet therapy (mostly aspirin) who initiated rivaroxaban, measuring indices of oxidative stress, endothelial function (nitric oxide bioavailability, ICAM-1/VCAM-1 levels), and platelet activation before and after rivaroxaban. In parallel, human endothelial cells were exposed to convulxin-activated platelet supernatants from healthy donors with or without rivaroxaban±clopidogrel, and assessed for NOX2 expression/activity, adhesion molecules, nitric oxide (NO) production, and tube-forming capacity. An ex vivo mouse model of angiotensin II-induced endothelial dysfunction was used to evaluate vascular relaxation responses after incubation with rivaroxaban and/or clopidogrel. RESULTS: production, downregulated endothelial NOX2 expression and sNOX2-dp release, and restored angiogenic capacity in endothelial cells exposed to activated platelets. Clopidogrel alone had negligible effects on these parameters. Notably, adding clopidogrel to rivaroxaban provided no additional endothelial benefit beyond rivaroxaban monotherapy. In an ex vivo hypertensive vessel model, rivaroxaban (but not clopidogrel) markedly improved endothelium-dependent relaxation. CONCLUSIONS: Rivaroxaban effectively preserves endothelial function by inhibiting platelet-induced NOX2-mediated oxidative stress and inflammation. The lack of any additive benefit from clopidogrel suggests that rivaroxaban alone may be mechanistically sufficient to counteract platelet-driven endothelial dysfunction. These findings reveal a novel vasoprotective mechanism for rivaroxaban and underscore its potential clinical value in mitigating vascular injury beyond its established antithrombotic effects.

Authors

Institutions

Publication Details

Journal
Journal of the American Heart Association
Published
2026-11-18
DOI
https://doi.org/10.1161/jaha.126.049175
Primary Topic
Nitric Oxide and Endothelin Effects
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Rivaroxaban Inhibits Platelet‐Driven NOX2‐Dependent Oxidative Injury to Endothelium

Silvano Garibaldi, Pasquale Pignatelli, Flavio Di Nonno, Antonio Sili Scavalli et al.
1 links
Journal of the American Heart Association
Nitric Oxide and Endothelin Effects
article

Rivaroxaban Inhibits Platelet‐Driven NOX2‐Dependent Oxidative Injury to Endothelium

Silvano Garibaldi, Pasquale Pignatelli, Flavio Di Nonno, Antonio Sili Scavalli, Giovanni Enrico Casciaro, Pietro Ameri, Emanuele Valeriani, Maurizio Forte, Rossella Marcucci, Giulia Ciarrocca Taranta, Alessandra D’Amico, Roberto Carnevale, Ernesto Greco, Vittorio Picchio, Italo Porto, Cristina Nocella, Patrizia Fabbi, Martina Berteotti, Giacomo Frati, Angela Leonardo
article en

Abstract

BACKGROUND: Endothelial dysfunction is a hallmark of cardiovascular disease, driven by oxidative stress, inflammation, and platelet activation. We hypothesized that the FXa inhibitor rivaroxaban, alone or combined with clopidogrel, could counteract platelet-induced oxidative injury to the endothelium and preserve endothelial function. METHODS: We conducted a prospective multicenter cohort clinical study in patients on chronic antiplatelet therapy (mostly aspirin) who initiated rivaroxaban, measuring indices of oxidative stress, endothelial function (nitric oxide bioavailability, ICAM-1/VCAM-1 levels), and platelet activation before and after rivaroxaban. In parallel, human endothelial cells were exposed to convulxin-activated platelet supernatants from healthy donors with or without rivaroxaban±clopidogrel, and assessed for NOX2 expression/activity, adhesion molecules, nitric oxide (NO) production, and tube-forming capacity. An ex vivo mouse model of angiotensin II-induced endothelial dysfunction was used to evaluate vascular relaxation responses after incubation with rivaroxaban and/or clopidogrel. RESULTS: production, downregulated endothelial NOX2 expression and sNOX2-dp release, and restored angiogenic capacity in endothelial cells exposed to activated platelets. Clopidogrel alone had negligible effects on these parameters. Notably, adding clopidogrel to rivaroxaban provided no additional endothelial benefit beyond rivaroxaban monotherapy. In an ex vivo hypertensive vessel model, rivaroxaban (but not clopidogrel) markedly improved endothelium-dependent relaxation. CONCLUSIONS: Rivaroxaban effectively preserves endothelial function by inhibiting platelet-induced NOX2-mediated oxidative stress and inflammation. The lack of any additive benefit from clopidogrel suggests that rivaroxaban alone may be mechanistically sufficient to counteract platelet-driven endothelial dysfunction. These findings reveal a novel vasoprotective mechanism for rivaroxaban and underscore its potential clinical value in mitigating vascular injury beyond its established antithrombotic effects.

Journal of the American Heart Association
Istituto Neurologico Mediterraneo (IT), European University of Rome (IT), Istituto Pasteur (IT), IRCCS Azienda Ospedaliera Metropolitana (IT), University of Florence (IT), University of Genoa (IT), Sapienza University of Rome (IT)
Good health and well-being
Nitric Oxide and Endothelin Effects
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon